Can hepatic stress, oxidative stress, magnesium insufficiency, and selenium-dependent deiodinase function reduce T4-to-T3 conversion and thyroid hormone action?

Hepatic dysfunction and selenium biology have established roles in peripheral thyroid-hormone metabolism, whereas oxidative stress and magnesium status remain mechanistically credible but clinically unproven contributors. The proposed convergence is therefore biologically coherent, but not demonstrated as a combined causal syndrome in ambulatory adults.

Clinical and metabolic evidence

• In nonthyroidal illness and significant liver dysfunction, lower T3 availability is linked to reduced hepatic T4-to-T3 activation, impaired hepatic thyroid-hormone uptake, altered clearance, and abnormal reverse-T3 handling. This can reduce circulating and tissue availability of active T3.
• This evidence primarily applies to substantial systemic illness, liver failure, or marked hepatic dysfunction—not necessarily to mild, isolated elevations in liver enzymes.
• Low-T3 patterns during serious illness generally reflect the systemic illness response rather than primary thyroid gland failure; thyroid-hormone treatment has not shown consistent clinical benefit in this setting.

Mechanistic basis

• Hepatic type 1 iodothyronine deiodinase (DIO1) is a major source of peripheral conversion of T4 to bioactive T3. In nonthyroidal illness with liver dysfunction, suppression of hepatic DIO1 provides a direct mechanism for reduced T3 generation.
• Selenium is an essential constituent of iodothyronine deiodinases. Accordingly, selenium-dependent deiodinase activity directly regulates systemic and local T3 production and thyroid-hormone action.
• Oxidative stress could disrupt redox-sensitive selenium-containing deiodinase systems. Magnesium could indirectly affect thyroid-hormone metabolism through ATP-dependent and mitochondrial processes. Direct human evidence linking either factor independently to measured conversion or tissue hormone action is lacking.

Clinical implications

• Selenium supplementation does not reliably increase FT3, FT4, total T3, or total T4 in randomized Hashimoto thyroiditis trials; benefit is most biologically plausible with documented deficiency.
• Magnesium supplementation has not conclusively improved thyroid function.

Bottom line

• Significant hepatic dysfunction and impaired selenium-dependent deiodinase activity can reduce T4-to-T3 conversion and thyroid-hormone action. Oxidative stress and magnesium insufficiency may contribute, but a clinically established combined effect has not been shown.